Capital Research Global Investors
ALNY icon

Capital Research Global Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capital Research Global Investors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.13B Buy
9,471,181
+2,691,473
+40% +$916M 0.49% 48
2025
Q4 		$2.7B Sell
6,779,708
-443,132
-6% -$196M 0.5% 41
2025
Q3 		$3.29B Buy
7,222,840
+31,184
+0.4% +$12.7M 0.62% 35
2025
Q2 		$2.35B Buy
7,191,656
+36,928
+0.5% +$10.2M 0.47% 50
2025
Q1 		$1.93B Buy
7,154,728
+186,215
+3% +$47.9M 0.42% 60
2024
Q4 		$1.64B Buy
6,968,513
+1,724,610
+33% +$454M 0.34% 67
2024
Q3 		$1.44B Buy
5,243,903
+1,988,255
+61% +$518M 0.3% 75
2024
Q2 		$791M Buy
3,255,648
+110,661
+4% +$17.5M 0.17% 112
2024
Q1 		$470M Buy
3,144,987
+214,908
+7% +$35.9M 0.11% 151
2023
Q4 		$561M Buy
2,930,079
+146,236
+5% +$24.9M 0.14% 144
2023
Q3 		$493M Buy
2,783,843
+429,082
+18% +$81.9M 0.14% 149
2023
Q2 		$447M Sell
2,354,761
-84,835
-3% -$16.8M 0.12% 153
2023
Q1 		$489M Buy
2,439,596
+1,607,479
+193% +$338M 0.14% 136
2022
Q4 		$198M Buy
+832,117
New +$177M 0.06% 215

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors's ALNY Position: Q1 2026 in Review

Capital Research Global Investors increased its Alnylam Pharmaceuticals (ALNY) stake by 40% in Q1 2026, buying an estimated $916M and bringing the position to 9,471,181 shares worth $3.13B. The position accounts for 0.49% of the portfolio, ranked #48.

Capital Research Global Investors first reported a position in ALNY in Q4 2022 and has held it in 14 quarters since. The position peaked at $3.29B in Q3 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Capital Research Global Investors held 9,471,181 shares of Alnylam Pharmaceuticals worth $3.13B as of Q1 2026.
  • Capital Research Global Investors bought 2,691,473 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $916M.
  • Alnylam Pharmaceuticals made up 0.49% of Capital Research Global Investors's portfolio in Q1 2026, its #48 holding.
  • Capital Research Global Investors first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Capital Research Global Investors's Alnylam Pharmaceuticals position peaked at $3.29B in Q3 2025.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.